Multi-domain CD1a antagonist/PD-1 agonist antibody molecules
AssigneeImmunocore Limited
InventorsAdam Curnock, David Overton
Life of this patent
Estimating the term…
Abstract
The present disclosure provides multi-domain molecules comprising, (i) a first binding domain that binds to PD-1, (ii) a second binding domain that binds to CD1a, and optionally, (iii) a half-life extending domain. Such multi-domain molecules are particularly useful in the development of soluble immunotherapeutic reagents for the treatment of autoimmune diseases, such as atopic dermatitis (AD).
Claims46
A multi-domain molecule comprising:
- (i) a first binding domain that binds to PD-1, wherein the first binding domain comprises a CDR1, a CDR2, and a CDR3 comprising the following sequences:
- (SEQ ID NO:
- 1)
- CDR1 - GFTFSSYA,
- (SEQ ID NO:
- 2)
- CDR2 - IASDGAST, and
- (SEQ ID NO:
- 3)
- CDR3 - CARGGYLTYDRY,
- and
- (ii) a second binding domain that binds to CD1a, wherein the second binding domain comprises a CDR1, a CDR2, and a CDR3 comprising the following sequences:
- CDR1—GRTFNPGDLMG (SEQ ID NO:
- 4),
- CDR2—AIKWGPTYYADSVKG (SEQ ID NO:
- 7), and
- CDR3—GSGTFSSNYRDFEY (SEQ ID NO:
- 10),
- wherein the C-terminus of the first binding domain is linked to the N-terminus of the second binding domain.
A multi-domain molecule comprising:
- (i) a first binding domain that binds to PD-1, wherein the first binding domain comprises a CDR1, a CDR2, and a CDR3 comprising the following sequences:
- (SEQ ID NO:
- 1)
- CDR1 - GFTFSSYA,
- (SEQ ID NO:
- 2)
- CDR2 - IASDGAST, and
- (SEQ ID NO:
- 3)
- CDR3 - CARGGYLTYDRY,
- and
- (ii) a second binding domain that binds to CD1a, wherein the second binding domain comprises a CDR1, a CDR2, and a CDR3 comprising the following sequences:
- (SEQ ID NO:
- 5)
- CDR1 - GRAFRPHNVMA,
- (SEQ ID NO:
- 8)
- CDR2 - AARWSGIYYAESVKG ,
- and
- (SEQ ID NO:
- 11)
- CDR3 - STAQDMTLALMSDYDY,
- wherein the C-terminus of the first binding domain is linked to the N-terminus of the second binding domain.
A multi-domain molecule comprising:
- (i) a first binding domain that binds to PD-1, wherein the first binding domain comprises a CDR1, a CDR2, and a CDR3 comprising the following sequences:
- (SEQ ID NO:
- 1)
- CDR1 - GFTFSSYA,
- (SEQ ID NO:
- 2)
- CDR2 - IASDGAST, and
- (SEQ ID NO:
- 3)
- CDR3 - CARGGYLTYDRY,
- and
- (ii) a second binding domain that binds to CD1a, wherein the second binding domain comprises a CDR1, a CDR2, and a CDR3 comprising the following sequences:
- (SEQ ID NO:
- 6)
- CDR1 - GRTFSPSDLMG,
- (SEQ ID NO:
- 9)
- CDR2 - AIKWGPTYYSDSVKG, and
- (SEQ ID NO:
- 12)
- CDR3 - GSSTFSANYRDYEY,
- wherein the C-terminus of the first binding domain is linked to the N-terminus of the second binding domain.
A single domain antibody that binds to CD1a, comprising a CDR1, CDR2, and CDR3, comprising the following amino acid sequences:
- (SEQ ID NO:
- 4)
- (a) CDR1 - GRTFNPGDLMG,
- (SEQ ID NO:
- 7)
- CDR2 - AIKWGPTYYADSVKG,
- and
- (SEQ ID NO:
- 10)
- CDR3 - GSGTFSSNYRDFEY;
- (SEQ ID NO:
- 5)
- (b) CDR1 - GRAFRPHNVMA,
- (SEQ ID NO:
- 8)
- CDR2 - AARWSGIYYAESVKG,
- and
- (SEQ ID NO:
- 11)
- CDR3 - STAQDMTLALMSDYDY;
- or
- (SEQ ID NO:
- 6)
- (c) CDR1 - GRTFSPSDLMG,
- (SEQ ID NO:
- 9)
- CDR2 - AIKWGPTYYSDSVKG,
- and
- (SEQ ID NO:
- 12)
- CDR3 - GSSTFSANYRDYEY.
Dependencies are inferred from the claim text.